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Abstract 
Background & aims. Hepatitis C virus (HCV) is bound to plasma lipoproteins and 
circulates as an infectious lipoviral particle (LVP). Experimental evidence indicates 
that LVPs have decreased susceptibility to antibody mediated neutralisation and 
higher infectivity. This study tested the hypothesis that LVPs are required to establish 
persistent infection, and conversely, low levels of LVP in recent HCV infection 
increase the probability of spontaneous HCV clearance.  
Methods. LVP in non-fasting plasma was measured using the concentration of HCV 
RNA bound to large >100 nM sized lipoproteins after ex vivo addition of a lipid 
emulsion, that represented the maximum concentration of LVP (maxi-LVP). This 
method correlated with LVP in fasting plasma measured using iodixanol density 
gradient ultracentrifugation. Maxi-LVP was measured in a cohort of 180 HCV 
participants with recent HCV infection and detectable HCV RNA from the Australian 
Trial in Acute Hepatitis C (ATAHC) and Hepatitis C Incidence and Transmission 
Study in prison (HITS-p) cohorts.  
Results. Spontaneous clearance occurred in 15% (27 of 180) of individuals. In 
adjusted analyses, low plasma maxi-LVP level was independently associated with 
spontaneous HCV clearance [≤827 IU/mL; adjusted odds ratio 3.98, 95% CI: 1.02, 
15.51, P=0.047)], after adjusting for interferon lambda-3 rs8099917 genotype, 
estimated duration of HCV infection and total HCV RNA level.  
Conclusions. Maxi-LVP is a biomarker for the maximum concentration of LVP in 
non-fasting samples. Low maxi-LVP level is an independent predictor of 
spontaneous clearance of acute HCV. 
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Key Points 
• Spontaneous clearance occurs in ~25% following exposure to hepatitis C 
virus (HCV). Lipoviral Particles (LVPs) are the infectious fraction of HCV 
associated with lipoproteins in plasma.  
• We investigated whether low levels of LVP are independently associated with 
spontaneous HCV clearance in 180 participants in the ATAHC and HITS-p 
studies of early HCV infection.  
• We measured the maximum concentration of LVP (maxi-LVP) using a size 
filtration method, demonstrating close correlation with iodixanol density 
gradient ultracentrifugation, following addition of lipid emulsion to control for 
post-prandial lipaemia in non-fasting samples. 
• Low maxi-LVP level is an independent predictor of spontaneous clearance in 
early HCV. 
 
Introduction  
An essential component of the hepatitis C virus (HCV) lifecycle is the formation of 
‘lipoviral particles’ (LVP) (1). HCV is co-assembled with the hepatocyte’s machinery 
for export of very-low density lipoproteins (VLDL) (2). LVP contain not only HCV viral 
proteins and RNA, but also have physical properties of lipoproteins, being of low-
buoyant density, large size and containing apolipoprotein’s B (apoB), apoE and 
apoA1 (3). The lipoprotein association  increases infectivity of LVPs (4, 5) and 
decreases susceptibility to antibody mediated neutralisation (6). We therefore 
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hypothesised that formation of LVP is likely to be important in the natural history of 
early acute HCV infection in determining the probability of spontaneous clearance or 
persistent infection.  
 
The natural history of acute HCV infection has not been fully defined, but 
spontaneous clearance occurs in ~25% of those exposed to the virus (7, 8). Factors 
related to innate immunity (9) and induction of interferon stimulated genes may be 
important for early spontaneous clearance (10, 11). Other factors that have been 
independently associated with spontaneous clearance include sex, interferon 
lambda-3 (IFNL3) genotype, interferon-gamma-inducible protein-10, HCV genotype, 
HIV infection and HBV infection (8, 11, 12). 
 
LVP have previously been measured in patients with chronic HCV infection in fasting 
plasma using iodixanol density gradient ultracentrifugation (13, 14). This method 
defined a low-density fraction (d <1.07 g/mL), in which all the apoB containing 
lipoproteins are captured and HCV RNA detected within this fraction was considered 
to represent apoB associated LVP (14). HCV RNA in the higher density fraction 
d>1.07 g/mL that did not contain apoB, were considered ‘non-LVPs’.  In chronic HCV 
genotype 1 infection, LVP and LVP ratios were associated with insulin resistance, 
triglycerides (14), apoE concentrations and sustained virological response to 
pegylated interferon and ribavirin therapy (15). Different metabolic correlations were 
identified when comparing LVP in HCV genotype 1 to genotype 3 (16). However, 
variability of density distribution in the post prandial state limits application of this 
method to non-fasting samples (17). In order to investigate LVP in non-fasting 
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samples from a unique cohort of recent HCV infection,  a modified LVP assay 
measuring sized large HCV particles >100nM after ex vivo addition of lipid emulsion 
(maxi-LVP) was used. It was hypothesised that concentrations of LVP will be higher 
in early acute HCV infection compared to later duration of infection and that lower 
LVP levels would independently predict spontaneous HCV clearance. Hence, we 
evaluated whether i) maxi-LVP is increased in early acute HCV infection (<26 weeks) 
compared to later (>26 weeks) duration of infection; and ii) the concentrations of 
maxi-LVP predict spontaneous clearance during recent (acute and early chronic) 
HCV infection.  
 
Patients and Methods  
Study Population and Design 
The role of LVPs during recent HCV infection was investigated using stored plasma  
and data from two studies of recent HCV infection. The methods of both studies 
have been previously described in detail (18, 19). The Australian Trial in Acute 
Hepatitis C (ATAHC) was a prospective study of the natural history and treatment of 
recent HCV (18). The Hepatitis C Incidence and Transmission Study in prison (HITS-
p) is an ongoing study of prison inmates at-risk of acute HCV in correctional centres 
(19). Stored plasma samples were used to measure maxi-LVP in both ATAHC and 
HITS-p acute HCV cohorts. 
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For inclusion, participants from these cohorts had to have recent HCV infection 
defined by an initial positive anti-HCV test and either 1) a negative anti-HCV test 
within two years prior to the initial positive anti-HCV test or 2) acute clinical hepatitis 
(either jaundice or ALT >400 IU/mL) within 12 months of the initial positive anti-HCV 
result.  
 
Among individuals with anti-HCV negative and HCV RNA positive at the time of 
recent HCV detection, the estimated date of HCV infection was 4 weeks prior to 
diagnosis date (20, 21). Among individuals with HCV seroconversion and no acute 
symptomatic infection, the estimated date of infection was calculated as the midpoint 
between the last negative anti-HCV and first positive anti-HCV or RNA test. Among 
individuals with acute symptomatic infection, the estimated date of infection was 
calculated as 6 weeks prior to the onset of acute clinical hepatitis (22). All 
participants provided written informed consent. The study protocols were approved 
by St Vincent’s Hospital Sydney, Corrective Services New South Wales, and Justice 
Health Human Research Ethics Committees. 
 
Laboratory testing 
Sample selection 
All participants with sufficient available EDTA or acid citrate dextrose (ACD) plasma 
samples that were HCV RNA positive at the time of acute HCV detection were 
identified. The laboratory analysis was conducted blinded to the outcomes. In 
addition, 30 participants from the ATAHC study with high volumes of available EDTA 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
or ACD plasma samples (>1 mL) were randomly selected for duplicate testing to 
calculate the coefficient of variation (CV) for the maxi-LVP methods described below.  
 
Maxi- LVP assay 
The maxi-LVP assay was performed by incubating 50 µL of EDTA or ACD plasma 
with an equal volume of diluted lipid emulsion, (27.8 µL of Intralipid 20% 
(SigmaAldrich) diluted in 2 mL PBS) at 37 °C for 2 hours. When the incubation was 
complete, the intralipid-plasma was then further diluted 1 in 20 with addition of 900 
µL of PBS. 200 µL of the dilute Intralipid-plasma sample was transferred to a  
Ultrafree ® MC Durapore ® PVDF membrane (0.1 µM) Millipore size filter (Merck-
Millipore Ultrafree UFC30VV00) and centrifuged at 10,000 x G for 30 minutes. All of 
the filtrate (HCV RNA bound to particles size <0.1 µM) was transferred to an 
Eppendorf containing Qiagen protease. HCV RNA retained by the filter (particle size 
>0.1 µM) was extracted by addition of Qiagen protease (25µL protease with 200 µL 
PBS) and vortexing for 15 seconds. 200 µL of RNA extraction lysis buffer was then 
added to the filters with further vortexing for 15 seconds. The contents (retentate) 
were then transferred to a new Eppendorf tube and incubated for 15 mins at 56 °C.  
Viral RNA was extracted from the filtrate and from the retentate using a Qiagen Virus 
spin Minelute Virus Spin kit according to the manufacturer’s instructions.  
 
HCV RNA quantitation 
HCV RNA from the retentate (maxi-LVP) and filtrate (non-LVP) were reverse 
transcribed using AMV Reverse Transcriptase (Promega) and sequence specific 
primer NCR3 as previously described (23). cDNA was quantitated using a two-step 
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Taq Man Real time PCR as previously described using primers NCR-3 and NCR-5 
and dual labelled probe SN1 to the 5’ UTR of the HCV genome (23).  
 
Maxi-LVP was defined as the HCV RNA concentration (IU/mL) in the retentate of the 
filter after incubation with dilute intralipid. HCV RNA was also measured from the 
filtrate (non-LVP) and the maxi-LVP ratio calculated as retentate / (retentate + 
filtrate).  
 
Paired stored EDTA plasma in 53 HCV genotype 1 patients were tested using the 
two LVP assays; i) iodixanol density gradient ultracentrifugation defined LVP as HCV-
RNA detected at density <1.07 g/ml (2), ii) Maxi-LVP assay defined LVP as HCV-
RNA retained by the 0.1 µM size filter, after incubation with a lipid emulsion. 
Pearson’s correlation was used to determine the agreement between the two LVP 
assays (figure 1). 
 
Study outcome 
The association of maxi-LVP and non-LVP levels at the first detection of HCV 
infection with spontaneous HCV clearance was investigated. Spontaneous clearance 
was defined as two subsequent consecutive undetectable HCV RNA tests (<10 
IU/mL) ≥ 4 weeks apart following documented infection. Treated individuals with an 
estimated duration of infection <26 weeks were excluded from analyses of 
spontaneous clearance to reduce misclassification bias because there is uncertainty 
around whether these individuals would have demonstrated spontaneous clearance 
in the absence of treatment. 
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Statistical analyses 
The co-efficient of variation (CV) of maxi-LVP was determined by calculating the 
standard deviation/mean of the maxi-LVP assay in the ATAHC cohort of 30 randomly 
selected non-fasting samples run in duplicate. Nonparametric statistical tests were 
used for analyses, given that maxi-LVP and non-LVP levels (IU/mL) and log10 
transformation of maxi-LVP and non-LVP levels (log IU/mL) were not normally 
distributed. Median maxi-LVP levels, non-LVP levels and maxi-LVP ratio were 
compared between spontaneous clearance and persistent infection groups using the 
Wilcoxon–Mann–Whitney test. The proportion of individuals with detectable and 
undetectable maxi-LVP was compared between spontaneous clearance and 
persistent infection groups using Chi Square test. Similarly, distribution of maxi-LVP 
levels, non-LVP levels and maxi-LVP ratio were compared between individuals with 
estimated duration of infection <26 weeks at the time of HCV detection (early acute 
HCV infection) and those with an estimated duration of infection >26 weeks at the 
time of HCV detection. 
 
The association of low maxi-LVP levels and non-LVP levels with spontaneous 
clearance was assessed using logistic regression. Low maxi-LVP levels and non-LVP 
levels were defined as equal or lower than median (i.e. ≤827 IU/mL as low maxi-LVP 
levels and ≤1854 IU/mL as low non-LVP levels). In the adjusted models, the 
association of low maxi-LVP levels and low non-LVP levels with spontaneous 
clearance was adjusted for potential confounders including interferon-lambda 
rs8099917 genotype, HCV RNA levels, and estimated duration of infection. Potential 
confounders in the adjusted models included variables associated with spontaneous 
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clearance in this study (P<0.200). All analyses were performed using Stata v12.0 
(College Station, TX, United States). 
 
Results 
Participant characteristics 
The baseline characteristics of the study cohorts are shown in Table 1. Among 206 
participants in ATAHC and HITS-p, 180 individuals had detectable HCV RNA at initial 
HCV diagnosis and are included in this analysis (69% male, 18% HIV infected, 
median total HCV RNA: 4.87 log10 IU/mL).  
 
Assay development and validation 
The validity of the maxi-LVP assay in comparison to iodixanol density gradient 
ultracentrifugation method was assessed by paired analysis using the two assays 
from the same stored samples. There was strong correlation between LVP (HCV 
RNA log10 IU/ml) as measured by iodixanol density gradient vs maxi-LVP methods 
(R2 57.2%, r = 0.756, P<0.001). The iodixanol ratio also correlated significantly with 
the maxi-LVP ratio (R2 36.9%, r=0.421, P=0.006). Likewise there was significant 
correlation between non LVP (HCV RNA log10 IU/ml) as measured by iodixanol 
density gradient (d>1.07g/ml) and HCV RNA in the size filtrate (R2 36.9%, r= 0.608, 
P<0.001) (figure 1). Bland-Altman plots describe the test agreement between the two 
assays (Figure 1 B and D). Maxi LVP and non-LVP consistently under-measured 
HCV RNA compared to iodixanol density gradients by -0.97 log10 IU/ml for LVP and 
-1.15 log10 IU/mL for non-LVP, which was not clinically significant for analysis in this 
study. 
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Maxi-LVP sensitivity and co-efficient of variation 
Maxi-LVP assay was performed in duplicate on 30 non-fasting samples from 
ATAHC. The CV varied according to baseline HCV RNA level. For samples with 
HCV RNA level >1,500 IU/ml, filtrate (non-LVP) CV = 0.09, retentate (Maxi-LVP) CV 
= 0.19, maxi-LVP ratio CV = 0.16. 
 
LVP-max in early (<26 weeks) vs late (>26 weeks) HCV infection 
At first acute HCV detection, the median maxi-LVP level was 827 IU/ml [inter-quartile 
range (IQR): 0, 6436], non-LVP level was 1854 IU/ml (IQR: 0, 19999) and maxi-LVP 
ratio was 0.30 (IQR: 0.03, 0.48). In early HCV infection (<26 weeks) there was a 
trend towards increased median maxi-LVP concentrations compared to later HCV 
infection (>26 weeks) [1140 IU/mL (IQR: 199, 8090)  vs. 686 IU/mL (IQR: 0, 4335); 
P=0.071; Figure 2). 
 
Maxi-LVP and spontaneous HCV clearance 
Spontaneous HCV clearance occurred in 15% (27 of 180) overall. Lower median 
maxi-LVP levels were observed among people with subsequent spontaneous 
clearance than in those subsequently developing persistent infection [253 IU/mL 
(IQR: 0, 2012) vs. 986 IU/mL (IQR: 116, 5761); P=0.074; Figure 3)].  
 
The proportion of individuals with spontaneous clearance was 9% (8 of 87) among 
those with plasma maxi-LVP levels >827 IU/mL (median) vs 20% with maxi-LVP 
levels ≤827 IU/mL (19 of 93; P=0.035). Of those with spontaneous clearance, maxi-
LVP were undetectable in 41%, compared to 24% in those developing persistent 
infection (P=0.060). 
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In adjusted analyses, low plasma maxi-LVP level (≤827 IU/mL) was independently 
associated with spontaneous HCV clearance [adjusted odds ratio (AOR) 3.98, 95% 
CI: 1.02, 15.51, P=0.047)], after adjusting for IFNL3 rs8099917 genotype, estimated 
duration of HCV infection and HCV RNA level (Table 2). In contrast, non-LVP was not 
independently associated with spontaneous HCV clearance after adjusting for IFNL3 
rs8099917 genotype, estimated duration of infection and HCV RNA level (Table 3) 
 
Discussion:  
This is the first study to report LVP in the natural history of recent HCV and 
spontaneous clearance. The key findings are that low maxi-LVP at the detection of 
recent HCV infection independently predicted subsequent spontaneous clearance. 
This was consistent with results demonstrating that people with spontaneous 
clearance had lower median maxi-LVP levels compared to those who developed 
persistent HCV infection. 
 
LVPs are considered to represent the infectious fraction of plasma by direct virus-
lipoprotein interactions (1). Analysis of this unique cohort of people with recent HCV 
infection permitted exploration of the hypothesis that formation of LVP in early 
infection influences the outcome of spontaneous clearance or persistent infection, 
independently of other host genetic and immune factors. Previous analysis of the 
ATAHC and HITS-p cohorts has indicated that factors associated with spontaneous 
clearance included IFNL3 genotype, female sex, and estimated duration of infection 
<26 weeks (8). These factors were taken into account in the multivariate analysis, 
and concentrations of maxi-LVP below the median value remained independently 
associated with spontaneous clearance.  
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High concentrations of LVP indicate that HCV has established efficient viral 
assembly within the liver by co-opting the secretory machinery of VLDL export from 
hepatocytes (1). The association of HCV with lipoproteins in vivo is dynamic and 
variable. Quantities of very low density LVP have previously been observed to 
increase after a high fat meal, and are rapidly cleared (17). Post prandially, HCV in 
plasma associates with both liver derived VLDL containing apoB100, and intestinally 
derived chylomicrons containing apoB48 (17, 24). In the fasting state, only a minority 
of HCV RNA (27-37%) were detectable in a very low density fraction (d<1.025 g/L), 
but following ex vivo addition of post prandial plasma from a healthy volunteer, the 
amount of HCV RNA in the very low density fraction increased (53-78%) (17). The 
significance of this observation is that measurement of LVP by density or size in 
randomly selected non-fasting samples will be subject to variation dependent on the 
nature and timing of sampling in relation to ingestion of the last meal. Previous work 
has reported that addition of a dilute lipid emulsion (Intralipid) increases 
concentrations of very low-density HCV RNA to the same extent as with addition of 
post-prandial plasma (17). These previous observations indicated therefore that the 
maximum concentration of LVP apparent post-prandially can be recapitulated by ex 
vivo addition of a lipid emulsion. In the present study, the property of re distribution of 
HCV RNA to large triglyceride rich lipoproteins has been utilised to devise a novel 
method to measure the maximum concentration of LVP (maxi-LVP), which 
fractionates non-fasting plasma using a size filter after ex vivo addition of a lipid 
emulsion. Thus ex vivo addition of lipid emulsion generates the maximum 
concentration of LVP and overcomes the limitation of not having fasting samples 
available in this unique cohort of early HCV. Maxi-LVP not only measures HCV RNA 
bound to large VLDL, but also measures HCV RNA that has redistributed onto large 
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sized lipid emulsion particles by ex vivo transfer during the incubation. Maxi-LVP 
may therefore measure both large sized, hepatocyte assembled LVPs and de novo 
LVPs formed by coalescence of smaller / high density sub-viral ‘empty’ LVPs (25) 
and HCV-RNA containing nucleocapsids or HCV RNA containing exosomes (26). 
The described phenomenon of HCV RNA redistributing onto large triglyceride rich 
lipoproteins including intestinally derived chylomicrons in the vascular compartment 
following ingestion of a high fat meal (17) leads to the hypothesis that this dynamic 
component of the HCV lifecycle may be an important factor in establishing persistent 
infection.  
 
The conceptual model of an LVP is one in which the virus is wholly or partially 
encapsulated within the native lipoprotein (2). Thus the lipoprotein masks viral 
epitopes exposed to antibody mediated neutralisation (3). Our data supports this 
model. There is considerable variation in the patterns of viraemia observed in acute 
HCV (27) particularly in the early stages, and divergence of viraemia does not 
become apparent until months 3-5 following exposure (28). Some of this variation 
could be explained by the interplay between LVPs and neutralising antibody 
responses to HCV. LVP have decreased susceptibility to antibody mediated 
neutralisation (6). Evaluation of broadly neutralising antibody responses in acute 
HCV has indicated that individuals that spontaneously clear HCV have cross-
reactive broadly neutralising antibody responses to heterologous viral pseudo-
particles that are rarely detected in chronic infection (29, 30). Our model implies that 
these neutralising antibody responses are more likely to occur in those with low or 
undetectable LVP concentrations. When broadly neutralising antibody responses 
have been studied longitudinally in chronic HCV infection, the literature supports the 
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model that immunological selection pressures drive viral escape mutations in defined 
neutralising epitopes, leading to loss of recognition by monoclonal antibodies against 
these epitopes and decreased neutralisation of corresponding pseudo-particles (31). 
We hypothesise that LVP may be increased in the early stages of acute infection 
prior to the occurrence of high titre neutralising antibody responses. In later chronic 
HCV infection, neutralising antibody responses may generate increased levels of 
immune complexed HCV, thereby decreasing the fraction of viral particles circulating 
as LVP. Taken together, these data support the model that HCV interacts with 
lipoproteins early in acute HCV infection and that this interaction influences the 
balance of probabilities of persistent infection or spontaneous clearance. Efficient 
formation of LVPs is likely to mask viral epitopes from antibody mediated 
neutralisation and support immune escape and establishment of persistent infection, 
whereas failure to form LVP exposes HCV to antibody mediated neutralisation, and 
favours spontaneous clearance. 
 
In conclusion, this study reports the application of a novel candidate viral biomarker 
(maxi-LVP) to a unique cohort of people with recent HCV. The data support the 
concept that LVPs are likely to be important in establishing persistent HCV infection. 
Future work is required to define the specific mechanisms and sequence variants 
that mediate HCV-lipoprotein association. Disruption of HCV-lipoprotein interactions 
may be relevant for development of an efficacious anti-HCV vaccine to ‘unmask’ viral 
epitopes from the LVP. 
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Table 1. Baseline characteristics of study cohorts 
 
Overall 
n (%) 
n=180 
ATAHC 
n (%) 
n=105 
HITS 
n (%) 
n=75 
Age; years; median (IQR) 29 (25, 37) 33 (26, 41) 27 (23, 30) 
Sex 
   
   Female 56 (31) 32 (30) 24 (32) 
   Male 124 (69) 73 (70) 51 (68) 
IFNL3 genotype (rs12979860) 
   
   TT/CT 90 (50) 53 (50) 37 (49) 
   CC 80 (44) 49 (47) 31 (41) 
   Unknown 10 (6) 3 (3) 7 (9) 
IFNL3 genotype (rs8099917) 
   
   GG/GT 71 (39) 41 (39) 30 (40) 
   TT 103 (57) 60 (57) 43 (57) 
   Unknown 6 (3) 4 (4) 2 (3) 
HCV genotype 
   
   Genotype non-1 90 (50) 54 (51) 36 (48) 
   Genotype 1 71 (39) 49 (47) 22 (29) 
    Unknown 19 (11) 2 (2) 17 (23) 
HCV RNA levels; log IU/mL; median 
(IQR) 4.8 (3.6, 5.7) 4.5 (3.3, 5.7) 4.9 (4.2, 5.7) 
Estimated time since infection 
   
    ≤ 26 weeks 89 (49) 48 (46) 41 (55) 
    > 26 weeks 91 (51) 57 (54) 34 (45) 
HIV co-infection 
   
    No 148 (82) 73 (71) 75 (100) 
    Yes 32 (18) 32 (30) 0 (0) 
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Table 2: Unadjusted and adjusted model evaluating the association of high plasma maxi-LVP (HCV RNA detected at size ≥100 
nM) with spontaneous clearance  
  
Unadjusted model Adjusted model 1*: Adjusted model 2** 
OR (95% CI) P Adjusted OR (95% CI). P Adjusted OR (95% CI). P 
Maxi-LVP 
  
    
    > 827 IU/mL 1.00  1.00  1.00  
    ≤ 827 IU/mL 2.53 (1.05, 6.14) 0.039 3.46 (1.33, 9.00) 0.011 3.98 (1.02, 15.51) 0.047 
Age  0.98 (0.93, 1.03) 0.338     
Sex 
  
    
   Female 1.00      
   Male 0.92 (0.38, 2.25) 0.857     
IFNL3 (rs12979860) 
  
    
   TT/CT 1.00      
   CC 0.56 (0.29, 1.10) 0.096     
IFNL3 (rs8099917) 
  
    
   GG/GT 1.00  1.00   1.00   
   TT 2.74 (1.10, 6.80) 0.030 3.20 (1.22, 8.36) 0.018 3.23 (1.23, 8.48) 0.017 
HCV genotype       
   Genotype non-1 1.00      
   Genotype 1 0.89 (0.37, 2.14) 0.795     
HCV RNA levels (log IU/mL) 0.77 (0.55, 1.07) 0.116   1.07 (0.66, 1.73) 0.778 
Estimated time since 
infection   
    
    ≤ 26 weeks 1.00  1.00  1.00  
    > 26 weeks 0.29 (0.11, 0.72) 0.008 0.25 (0.09, 0.65) 0.005 0.24 (0.09, 0.64) 0.004 
* Adjusted for the variables with a P<0.05 in unadjusted analysis, including interferon lambda genotype (rs8099917) and estimated time since infection 
** Adjusted for the variables with a P<0.20 in unadjusted analysis, including interferon lambda genotype (rs8099917), estimated time since infection and HCV 
RNA levels 
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Table 3: Unadjusted and adjusted models evaluating the association of high plasma non-LVP levels (HCV RNA detected at size 
<100 nM) with spontaneous clearance  
  
Unadjusted model Adjusted model 1* Adjusted model 2** 
OR (95% CI) P AOR (95% CI). P AOR (95% CI). P 
Non-LVP 
  
    
    > 1854 IU/mL 1.00  1.00  1.00  
    ≤ 1854 IU/mL 2.47 (1.02, 5.98) 0.045 2.63 (1.03, 6.65) 0.042 2.48 (0.57, 10.72) 0.225 
Age  0.98 (0.93, 1.03) 0.338     
Sex 
  
    
   Female 1.00      
   Male 0.92 (0.38, 2.25) 0.857     
IFNL3 genotype (rs12979860) 
  
    
   TT/CT 1.00      
   CC 0.56 (0.29, 1.10) 0.096     
IFNL3 genotype (rs8099917) 
  
    
   GG/GT 1.00  1.00   1.00   
   TT 2.74 (1.10, 6.80) 0.030 2.83 (1.12, 7.16) 0.028 2.83 (1.12, 7.18) 0.028 
HCV genotype       
   Genotype non-1 1.00      
   Genotype 1 0.89 (0.37, 2.14) 0.795     
HCV RNA levels (log IU/mL) 0.77 (0.55, 1.07) 0.116   0.97 (0.58, 1.64) 0.919 
Estimated time since infection       
    ≤ 26 weeks 1.00  1.00  1.00  
    > 26 weeks 0.29 (0.11, 0.72) 0.008 0.28 (0.11, 0.72) 0.008 0.28 (0.11, 0.72) 0.008 
* Adjusted for the variables with a P<0.05 in unadjusted analysis, including interferon lambda genotype (rs8099917) and estimated time since infection 
** Adjusted for the variables with a P<0.20 in unadjusted analysis, including interferon lambda genotype (rs8099917), estimated time since infection and HCV 
RNA levels 
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Figure Legends: 
Figure 1: Maxi-LVP assay development and validation. 
 
Hepatitis C virus lipoviral particles (LVP) were measured by two methods using the 
same fasting EDTA plasma samples. The reference assay defined LVP as low 
density HCV RNA (d <1.07 g / ml), measured from 500 µL of plasma using iodixanol 
density gradient ultracentrifugation as described previously (14, 15). Maxi-LVP were 
measured in 50 µL of EDTA plasma, and defined as HCV RNA retained by a size 
filter (100, 200 and 450 nM), after incubation with diluted lipid emulsion (to mimic 
post prandial lipaemia), Intralipid 20% (SigmaAldrich) or PBS as a control, at 37 °C 
for 2 hours. The greatest correlation coefficient between iodixanol gradient low 
density LVP and size filter retained HCV RNA was obtained using addition of dilute 
intralipid-plasma and fractionation using a 100 nM Durapore size filter (panel A). A 
Bland-Altman plot describes the test agreement between maxi-LVP and iodixanol 
LVP log10 IU/mL (panel B). The mean difference was -0.97 log10 IU/mL, standard 
deviation 0.47, (95% CI -1.11, -0.83). The upper limit of agreement (ULA) was -0.83, 
and lower limit of agreement (LLA) -1.89 log10 IU/mL.  
Non-LVP were defined from a reference iodixanol density gradient assay as HCV 
RNA detected at high density (d>1.07 g/mL). There was significant correlation 
between the filtrate non-LVP (size <100nM), after addition of dilute Intralipid ( panel 
C). A Bland-Altman plot describes the test agreement between maxi-LVP filtrate and 
iodixanol non-LVP log10 IU/mL (panel D). The mean difference was -1.15 log10 
IU/mL, standard deviation 0.57, (95% CI -1.32, -0.98). The upper limit of agreement 
(ULA) was -0.03 and lower limit of agreement (LLA)  -2.27 log10 IU/mL. 
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